SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (194)8/30/1999 3:41:00 PM
From: RWReeves  Read Replies (1) of 427
 
It, could be that Avalon had already covered by this time and got spanked with the rest of us. In any case, just shows the volatility of the market that a stock loses a third of it's value on a non-event like this. I can't say for certain, but it sounds pretty minor- I've had similar types of discussions with the FDA and resolved them in a single phone conference with no loss of stride.

I do know what the agency is asking for at the moment in MAB therapeutics. Some of it is a little unusual- CBER is very concerned about a couple of special areas and is routinely asking for more information in a couple of areas-(mainly the documentation of animal origin and history of cell lines because of TSE's, and an unusually keen interest in HAMA responses in the clinicals). IF (big IF) that's all it is, should not be a big deal.

Press release didn't sound like a big deal- As long as you don't need to go back to the clinics or re-do manufacturing studies should be a quick turn.

My continued estimation is that CBER WANTS to approve Bexxar for internal reasons, but that with any new drug or biologic that safety comes first.

My stop got creamed with everybody else but I've been nibbling back in. Imagine if this happened to the DOW. Amazing.

RWR
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext